Profile data is unavailable for this security.
About the company
BioAtla, Inc. is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of solid tumor cancer. The Company’s product candidates include Mecbotamab vedotin (BA3011), Ozuriftabmab vedotin (BA3021), BA3071, and BA3182. Its lead product candidate, BA3011, is a conditionally active biologics (CAB) antibody-drug conjugates (ADC) that targets AXL, which is a protein kinase receptor. The BA3071 is a potential therapeutic for multiple solid tumor types, including soft tissue and bone sarcoma, and non-small cell lung cancer (NSCLC). BA3021 is developing a CAB antibody drug conjugate directed against a receptor tyrosine kinase such as orphan receptor 2 (ROR2). BA3071 is a CAB anti-CTLA-4 antibody that is being developed as a therapeutic for multiple solid tumor indications. BA3182 is designed with an EpCAM binding domain and a CD3 binding domain, both binding domains with CAB activity (Dual-CAB), for the treatment of advanced adenocarcinoma.
- Revenue in USD (TTM)0.00
- Net income in USD-104.56m
- Incorporated2019
- Employees65.00
- LocationBioatla Inc11085 Torreyana RoadSAN DIEGO 92121United StatesUSA
- Phone+1 (858) 558-0708
- Fax+1 (858) 558-0701
- Websitehttps://www.bioatla.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IO Biotech Inc | 0.00 | -88.00m | 76.42m | 68.00 | -- | 0.7938 | -- | -- | -1.44 | -1.44 | 0.00 | 1.46 | 0.00 | -- | -- | 0.00 | -76.85 | -- | -86.10 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -20.47 | -- | -- | -- |
| Chimerix Inc | 144.00k | -84.70m | 77.09m | 72.00 | -- | 0.4955 | -- | 535.34 | -0.9507 | -0.9507 | 0.0016 | 1.74 | 0.0007 | -- | 1.86 | 2,000.00 | -40.37 | -30.45 | -44.33 | -34.09 | 10.42 | -- | -58,820.14 | -442.93 | -- | -- | 0.00 | -- | -99.04 | -46.24 | -147.68 | -- | -13.24 | -- |
| Boundless Bio Inc | 0.00 | -57.72m | 77.22m | 72.00 | -- | 0.4308 | -- | -- | -2.60 | -2.60 | 0.00 | 8.05 | 0.00 | -- | -- | 0.00 | -33.64 | -- | -35.41 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -7.70 | -- | -- | -- |
| PMV Pharmaceuticals Inc | 0.00 | -48.88m | 77.79m | 63.00 | -- | 0.363 | -- | -- | -0.9662 | -0.9662 | 0.00 | 4.16 | 0.00 | -- | -- | 0.00 | -20.38 | -21.16 | -21.39 | -21.91 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 5.94 | -- | 16.31 | -- |
| Sellas Life Sciences Group Inc | 0.00 | -34.44m | 78.49m | 16.00 | -- | 24.19 | -- | -- | -0.934 | -0.934 | 0.00 | 0.0504 | 0.00 | -- | -- | 0.00 | -204.48 | -111.48 | -838.03 | -184.29 | -- | -- | -- | -1,289.42 | -- | -- | 0.00 | -- | -100.00 | -- | 9.59 | -- | -- | -- |
| Omega Therapeutics Inc | 6.31m | -78.90m | 78.87m | 93.00 | -- | 3.00 | -- | 12.49 | -1.43 | -1.43 | 0.1145 | 0.4762 | 0.0318 | -- | 6.67 | 67,892.48 | -39.72 | -- | -46.68 | -- | -- | -- | -1,249.54 | -- | -- | -- | 0.3917 | -- | 49.25 | -- | 5.13 | -- | -- | -- |
| Renovaro Inc | 0.00 | -88.12m | 79.76m | 11.00 | -- | 0.473 | -- | -- | -1.08 | -1.08 | 0.00 | 1.14 | 0.00 | -- | -- | 0.00 | -60.56 | -27.81 | -68.21 | -28.44 | -- | -- | -- | -- | -- | -24.38 | 0.0405 | -- | -- | -- | 65.02 | -- | -0.1538 | -- |
| Bioatla Inc | 0.00 | -104.56m | 80.24m | 65.00 | -- | 2.56 | -- | -- | -2.18 | -2.18 | 0.00 | 0.6491 | 0.00 | -- | -- | 0.00 | -84.23 | -48.72 | -106.06 | -57.35 | -- | -- | -- | -6,651.71 | -- | -- | 0.00 | -- | -- | -- | -15.95 | -- | -37.01 | -- |
| Vistagen Therapeutics Inc | 970.40k | -33.19m | 81.03m | 41.00 | -- | 0.7732 | -- | 83.50 | -1.53 | -1.53 | 0.0386 | 3.87 | 0.0151 | -- | -- | 24,882.05 | -51.63 | -62.84 | -56.12 | -68.03 | -- | -- | -3,420.44 | -5,768.52 | -- | -- | 0.00 | -- | 568.10 | -- | 50.44 | -- | -18.91 | -- |
| Cidara Therapeutics Inc | 31.58m | -116.17m | 81.78m | 69.00 | -- | 0.4055 | -- | 2.59 | -25.49 | -25.30 | 6.95 | 28.66 | 0.2617 | -- | 8.06 | 457,623.20 | -96.27 | -65.23 | -136.45 | -154.37 | 91.14 | -- | -367.91 | -100.61 | -- | -- | 0.0053 | -- | -0.8425 | -- | 31.72 | -- | 23.33 | -- |
| Milestone Pharmaceuticals Inc | 0.00 | -48.41m | 82.57m | 47.00 | -- | 2.58 | -- | -- | -1.01 | -1.01 | 0.00 | 0.6003 | 0.00 | -- | -- | 0.00 | -51.98 | -48.44 | -55.36 | -51.56 | -- | -- | -- | -1,267.25 | -- | -- | 0.6171 | -- | -80.00 | -- | -2.22 | -- | 86.23 | -- |
| Adlai Nortye Ltd (ADR) | 5.00m | -54.07m | 82.66m | 127.00 | -- | 1.55 | -- | 16.53 | -6.21 | -6.21 | 0.2465 | 1.45 | -- | -- | -- | 39,370.08 | -- | -- | -- | -- | -- | -- | -1,081.30 | -- | -- | -- | 0.4255 | -- | -- | -- | -78.38 | -- | -- | -- |
| Aclaris Therapeutics Inc | 32.02m | -58.68m | 83.47m | 91.00 | -- | 0.6237 | -- | 2.61 | -0.8267 | -0.8267 | 0.4509 | 1.88 | 0.1614 | -- | 84.70 | 351,824.20 | -29.58 | -47.29 | -32.76 | -53.87 | 42.63 | 44.00 | -183.28 | -549.18 | -- | -- | 0.00 | -- | 5.03 | 38.41 | -1.81 | -- | -0.703 | -- |
| Benitec Biopharma Inc | 7.00k | -21.69m | 84.32m | 18.00 | -- | 1.98 | -- | 12,045.71 | -9.87 | -9.87 | 0.0031 | 4.22 | 0.0006 | -- | 0.1284 | 388.89 | -186.85 | -83.43 | -260.89 | -98.77 | 1,542.86 | 96.86 | -309,885.70 | -468.04 | -- | -307.03 | 0.00 | -- | 2.74 | -53.84 | -7.44 | -- | -56.51 | -- |
Data as of Sep 19 2024. Currency figures normalised to Bioatla Inc's reporting currency: US Dollar USD
27.86%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Soleus Capital Management LP (Investment Management)as of 19 Aug 2024 | 2.64m | 5.47% |
| Millennium Management LLCas of 05 Aug 2024 | 2.41m | 5.00% |
| The Vanguard Group, Inc.as of 30 Jun 2024 | 1.87m | 3.87% |
| Morgan Stanley & Co. LLCas of 30 Jun 2024 | 1.84m | 3.81% |
| Tang Capital Management LLCas of 30 Jun 2024 | 1.37m | 2.84% |
| BlackRock Fund Advisorsas of 30 Jun 2024 | 759.56k | 1.57% |
| DWS Investment Management Americas, Inc.as of 30 Jun 2024 | 670.00k | 1.39% |
| AQR Capital Management LLCas of 30 Jun 2024 | 636.14k | 1.32% |
| Scion Asset Management LLCas of 30 Jun 2024 | 633.96k | 1.31% |
| Renaissance Technologies LLCas of 30 Jun 2024 | 625.50k | 1.29% |
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
